MX2021011007A - Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco. - Google Patents

Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco.

Info

Publication number
MX2021011007A
MX2021011007A MX2021011007A MX2021011007A MX2021011007A MX 2021011007 A MX2021011007 A MX 2021011007A MX 2021011007 A MX2021011007 A MX 2021011007A MX 2021011007 A MX2021011007 A MX 2021011007A MX 2021011007 A MX2021011007 A MX 2021011007A
Authority
MX
Mexico
Prior art keywords
drug
diabetes
treating
preventing complications
complications
Prior art date
Application number
MX2021011007A
Other languages
English (en)
Inventor
Keita Shibata
Ryosuke Ryosuke
Terumasa Hashimoto
Koji Nobe
Original Assignee
Univ Showa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Showa filed Critical Univ Showa
Publication of MX2021011007A publication Critical patent/MX2021011007A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un fármaco que contiene un compuesto representado por la fórmula (I) como un ingrediente activo, usado para las complicaciones de la diabetes.
MX2021011007A 2019-03-12 2020-03-12 Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco. MX2021011007A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019044670 2019-03-12
PCT/JP2020/010967 WO2020184691A1 (ja) 2019-03-12 2020-03-12 薬剤及び該薬剤を用いて糖尿病合併症を治療又は予防する方法

Publications (1)

Publication Number Publication Date
MX2021011007A true MX2021011007A (es) 2022-03-11

Family

ID=72426033

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011007A MX2021011007A (es) 2019-03-12 2020-03-12 Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco.

Country Status (15)

Country Link
US (1) US20220218664A1 (es)
EP (1) EP3939659A4 (es)
JP (1) JPWO2020184691A1 (es)
KR (1) KR20220009371A (es)
CN (1) CN114126711A (es)
AU (1) AU2020238177A1 (es)
BR (1) BR112021018084A8 (es)
CA (1) CA3133204A1 (es)
CL (1) CL2021002373A1 (es)
EA (1) EA202192483A1 (es)
IL (1) IL286289A (es)
MX (1) MX2021011007A (es)
PE (1) PE20220333A1 (es)
SG (1) SG11202109982YA (es)
WO (1) WO2020184691A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220040294A (ko) * 2020-09-23 2022-03-30 씨엔지바이오 주식회사 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물
EP4293028A1 (en) * 2021-02-10 2023-12-20 Shanghai Senhui Medicine Co., Ltd. Smtp-7 derivative and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05176782A (ja) * 1992-01-08 1993-07-20 Taisho Pharmaceut Co Ltd Ｎｇｆ作用増強因子
JP2004224737A (ja) 2003-01-23 2004-08-12 Ttc:Kk 新規トリプレニルフェノール化合物
JP4313049B2 (ja) * 2003-01-23 2009-08-12 株式会社ティーティーシー 血管新生関連疾患の予防又は治療用医薬組成物
EP1944027A4 (en) 2005-10-06 2009-08-19 Univ Tokyo Nat Univ Corp PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF NEPHRITIS AND METHOD FOR PRODUCING THE SAME
CN102304131B (zh) 2006-03-27 2014-07-16 农工大Tlo株式会社 三异戊二烯基酚化合物、三异戊二烯基酚化合物的制造方法和血栓溶解促进剂
JPWO2010110026A1 (ja) * 2009-03-25 2012-09-27 国立大学法人東京農工大学 メタボリックシンドローム、肥満、高血糖症、高脂血症および／又は脂肪肝のための医薬組成物
ES2476041T3 (es) * 2009-07-06 2014-07-11 National University Corporation Tokyo University Of Agriculture And Technology Agente citoprotector trifenilfen�lico
WO2011125930A1 (ja) * 2010-04-02 2011-10-13 日本製薬株式会社 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤
JP2019044670A (ja) 2017-08-31 2019-03-22 スズキ株式会社 内燃機関の排出ガス浄化システム

Also Published As

Publication number Publication date
IL286289A (en) 2021-10-31
PE20220333A1 (es) 2022-03-14
BR112021018084A2 (es) 2021-12-21
EP3939659A4 (en) 2022-12-21
WO2020184691A1 (ja) 2020-09-17
JPWO2020184691A1 (es) 2020-09-17
BR112021018084A8 (pt) 2022-10-04
CL2021002373A1 (es) 2022-06-17
SG11202109982YA (en) 2021-10-28
CA3133204A1 (en) 2020-09-17
US20220218664A1 (en) 2022-07-14
EP3939659A1 (en) 2022-01-19
EA202192483A1 (ru) 2021-12-24
KR20220009371A (ko) 2022-01-24
AU2020238177A1 (en) 2021-11-04
CN114126711A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
PH12020500673A1 (en) Compounds
MY190137A (en) Noxious organism control agent composition for agricultural and horticultural applications, and method for using said composition
EP4269440A3 (en) Composition for treating il-6-related diseases
MX2021014350A (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos.
MX2021006695A (es) Moduladores de trex1.
PH12020500446A1 (en) Bisamide sarcomere activating compounds and uses thereof
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
SG11201810704WA (en) Sulfonamide compound or salt thereof
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2021003686A (es) Medicamento para el tratamiento de la tos cronica.
PH12019500394A1 (en) Bicyclic nitrogenated heterocyclic compound
PH12020551486A1 (en) Cyclopentane-based modulators of sting (stimulator of interferon genes)
MX2021004474A (es) Compuestos que contienen deuterio.
MX2021011007A (es) Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco.
MX2021013429A (es) Composiciones farmaceuticas inyectables y usos de las mismas.
PH12019502078A1 (en) Plant disease control agent
MX2021015188A (es) Moduladores de nueva generacion del estimulador de genes de interferon (sting).
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
CA3035115C (en) Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof
MX2020006055A (es) Composiciones farmaceuticas implantables de isoxazolina y usos de las mismas.
GEP20247590B (en) Antibacterial quinolines
AU2017370226A1 (en) Pharmaceutical composition containing insulin-like growth factor-2 and use thereof
MX2022008665A (es) Nuevo derivado de pirazol.
MX2022008487A (es) Degradadores de smarca2-vhl.